We have designed a study to detect molecular alterations (p53 mutations and amplifications of HER-2/neu and PRAD1) and protein expression products that may serve independently or jointly with histopathology to improve predictive capability for breast cancer. The study utilizes surgical specimens derived from a cohort of 6805 women who underwent biopsy for non-malignant breast disease at the Mayo Rochester-affiliated hospitals from January 1, 1967, to December 31, 1981. The cohort was followed until January l, 1987, during which time 236 cases of breast cancer occurred. Comparable women who did not develop breast cancer during the same interval have been selected as controls. The primary objectives of the study are: 1. To determine the frequency of p53 mutations and related immunohistochemical (IHC) markers in surgical specimens from women with benign breast disease. 2. To compare the pattern of p53 mutations (and related IHC markers) in paired benign and malignant tissues. 3. To determine whether the subsequent tumors that emerge from p53 positive women differ from p53 negative women in the profile of molecular mutations at p53, HER-2, and PRAD1, and in histologic appearance of the tumors. 4. To determine whether selected IHC markers in benign breast disease may define breast cancer risk. 5. To determine if the presence of these molecular lesions or IHC markers, in conjunction with histologic characteristics and epidemiologic risk factors, is predictive of eventual progression to breast cancer. Using novel laboratory techniques for detecting molecular lesions in minute quantities of DNA from formalin-fixed, paraffin-embedded sections, we are examining tissues from both benign and malignant lesions. Recent analyses have detected p53 mutations in 8% of the benign breast samples tested, but no evidence of gene amplification at the HER-2 and the PRAD1 loci. Our proposed study will complete the molecular analysis of benign breast tissue centering on p53 and consequences of p53 abnormalities to determine if these alterations predict the subsequent development of breast cancer. This study will provide information on the role of genetic and immunohistochemical markers in benign breast disease and will evaluate the utility of these markers in identifying women at high risk of breast cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA058223-06
Application #
6237356
Study Section
Project Start
1997-08-05
Project End
1998-07-31
Budget Start
1996-10-01
Budget End
1997-09-30
Support Year
6
Fiscal Year
1997
Total Cost
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
078861598
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Kumar, Sunil; Lindsay, Daniel; Chen, Q Brent et al. (2018) Tracking plasma DNA mutation dynamics in estrogen receptor positive metastatic breast cancer with dPCR-SEQ. NPJ Breast Cancer 4:39
Smith, Christof C; Beckermann, Kathryn E; Bortone, Dante S et al. (2018) Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. J Clin Invest 128:4804-4820
Wheeler, Stephanie B; Spencer, Jennifer C; Pinheiro, Laura C et al. (2018) Financial Impact of Breast Cancer in Black Versus White Women. J Clin Oncol 36:1695-1701
Hong, Chi-Chen; Sucheston-Campbell, Lara E; Liu, Song et al. (2018) Genetic Variants in Immune-Related Pathways and Breast Cancer Risk in African American Women in the AMBER Consortium. Cancer Epidemiol Biomarkers Prev 27:321-330
Tanioka, Maki; Mott, Kevin R; Hollern, Daniel P et al. (2018) Identification of Jun loss promotes resistance to histone deacetylase inhibitor entinostat through Myc signaling in luminal breast cancer. Genome Med 10:86
Tanioka, Maki; Fan, Cheng; Parker, Joel S et al. (2018) Integrated Analysis of RNA and DNA from the Phase III Trial CALGB 40601 Identifies Predictors of Response to Trastuzumab-Based Neoadjuvant Chemotherapy in HER2-Positive Breast Cancer. Clin Cancer Res 24:5292-5304
Mundt, Filip; Rajput, Sandeep; Li, Shunqiang et al. (2018) Mass Spectrometry-Based Proteomics Reveals Potential Roles of NEK9 and MAP2K4 in Resistance to PI3K Inhibition in Triple-Negative Breast Cancers. Cancer Res 78:2732-2746
Takaku, Motoki; Grimm, Sara A; Roberts, John D et al. (2018) GATA3 zinc finger 2 mutations reprogram the breast cancer transcriptional network. Nat Commun 9:1059
Butler, Eboneé N; Bensen, Jeannette T; Chen, Mengjie et al. (2018) Prediagnostic Smoking Is Associated with Binary and Quantitative Measures of ER Protein and ESR1 mRNA Expression in Breast Tumors. Cancer Epidemiol Biomarkers Prev 27:67-74
Echavarria, Isabel; López-Tarruella, Sara; Picornell, Antoni et al. (2018) Pathological Response in a Triple-Negative Breast Cancer Cohort Treated with Neoadjuvant Carboplatin and Docetaxel According to Lehmann's Refined Classification. Clin Cancer Res 24:1845-1852

Showing the most recent 10 out of 598 publications